Clinical Trials | March 12, 2024
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The institution will be spread over an area of more than 8 acres
These approvals mark significant progress for Venus Remedies in expanding its market presence
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Collaborative Research in AYUSH is extremely important as it bridges the gap between traditional knowledge and modern scientific research
With this, the total number of Patents granted to company for its innovative processes and technology stands at 9
Launch of Indian public health standards for Ayush healthcare facilities
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Subscribe To Our Newsletter & Stay Updated
